#1 Clinical Trials Search in Europe

2′-O-(2-Methoxyethyl)-D-Ribose Antisense Oligonucleotide Targeting Glial Fibrillary Acidic Protein Messenger Ribonucleic Acid

This article discusses the clinical trials of ION373, a novel drug designed to treat Alexander Disease. ION373 is a 2′-O-(2-Methoxyethyl)-D-Ribose Antisense Oligonucleotide that targets the Glial Fibrillary Acidic Protein (GFAP) messenger RNA. The trials aim to evaluate the drug’s efficacy, safety, and effects on patients with this rare genetic disorder. The study involves multiple phases and includes both double-blind and open-label periods to thoroughly assess the drug’s potential in improving or stabilizing various aspects of Alexander Disease.

Table of Contents

What is ION373?

ION373, also known as ION-1166998 or IONIS GFAP-Rx, is an innovative medication being developed to treat Alexander Disease[1]. It belongs to a class of drugs called antisense oligonucleotides, which are specially designed molecules that can influence how genes work in our bodies. ION373 is administered through a method called intrathecal injection, which means it’s delivered directly into the fluid surrounding the brain and spinal cord[1].

Alexander Disease: An Overview

Alexander Disease is a rare genetic condition that affects the nervous system[1]. It’s caused by mutations in a gene called GFAP (Glial Fibrillary Acidic Protein). This disease can impact various functions of the body, including movement, speech, and cognitive abilities. Currently, there are no approved treatments that directly target the underlying cause of Alexander Disease, which is why the development of ION373 is so important.

How ION373 Works

ION373 is designed to target the messenger RNA (mRNA) of the GFAP gene[1]. In simple terms, it aims to reduce the amount of abnormal GFAP protein produced in the body. By doing this, ION373 hopes to slow down or potentially stop the progression of Alexander Disease. This approach is innovative because it addresses the root cause of the disease at the genetic level.

Clinical Trial Details

A clinical trial is currently underway to evaluate the effectiveness and safety of ION373 in patients with Alexander Disease[1]. This study, known as ION373-CS1, is a Phase 1-3 trial, which means it will assess the drug’s safety, determine the right dosage, and evaluate its effectiveness all in one study.

Eligibility Criteria

The study is open to patients with Alexander Disease who meet certain criteria[1]. Some key eligibility factors include:

  • Age range: 2 to 65 years old (with a special sub-study for patients under 2 years)
  • Confirmed genetic mutation in the GFAP gene
  • Ability to walk or sit with minimal assistance (depending on age)
  • Stable medications and therapies for at least 3 months before screening

There are also several exclusion criteria, such as certain medical conditions or previous treatments that might interfere with the study results or pose additional risks to participants.

Study Objectives and Endpoints

The main goal of this study is to see if ION373 can improve or stabilize gross motor function in patients with Alexander Disease[1]. This will be primarily measured by looking at changes in a test called the 10-meter walk test (10MWT).

The study will also look at other important aspects of the disease, including:

  • Changes in patients’ most bothersome symptoms
  • Quality of life improvements
  • Changes in fine motor skills
  • Improvements in gastrointestinal symptoms
  • Changes in adaptive behavior and autonomic symptoms

Study Design

The clinical trial is divided into four main periods[1]:

  1. Double-Blind Treatment Period (60 weeks): Patients will receive either ION373 or a placebo. Neither the patients nor the doctors will know who is receiving the actual drug.
  2. Open-Label Treatment Period (60 weeks): All patients will receive ION373 during this phase.
  3. Long-Term Extension (120 weeks): Patients will continue to receive ION373 to assess its long-term effects.
  4. Post-Treatment Follow-Up (28 weeks): Patients will be monitored after stopping the treatment to ensure safety and observe any lasting effects.

Potential Benefits and Considerations

While ION373 shows promise, it’s important to remember that it’s still being studied[1]. Potential benefits could include improved motor function, better quality of life, and slowed disease progression. However, as with any experimental treatment, there may be risks and side effects that are not yet fully understood.

Participating in this clinical trial offers patients the opportunity to potentially access a cutting-edge treatment before it’s widely available. It also contributes to the advancement of medical knowledge about Alexander Disease, which could benefit future patients.

Aspect Details
Drug Name ION373 (2′-O-(2-Methoxyethyl)-D-Ribose Antisense Oligonucleotide)
Target Condition Alexander Disease
Study Type Phase 1-3, Double-Blind, Randomized, Placebo-Controlled
Main Objective Evaluate efficacy in improving or stabilizing gross motor function
Study Duration Approximately 5 years (including follow-up)
Administration Method Intrathecal injection
Key Eligibility Criteria Ages 2-65, confirmed GFAP gene mutation, stable medications for 3 months
Primary Endpoint Percent change from Baseline to Week 61 in the 10-meter walk test

FAQ

  • What is ION373 and how does it work? ION373 is a type of drug called an antisense oligonucleotide. It works by targeting the messenger RNA of a protein called Glial Fibrillary Acidic Protein (GFAP), which is involved in Alexander Disease. By doing this, ION373 aims to reduce the harmful effects of the disease on patients.
  • Who can participate in the ION373 clinical trials? The trials are primarily for patients aged 2 to 65 years old with a confirmed diagnosis of Alexander Disease. There are specific requirements for mobility and stability of current treatments. Younger patients (under 2 years) may be eligible for an open-label sub-study.
  • How is ION373 administered to patients? ION373 is administered intrathecally, which means it's injected directly into the fluid surrounding the brain and spinal cord. This is done through a procedure called a lumbar puncture.
  • How long do the clinical trials for ION373 last? The full study is composed of several periods: a 60-week double-blind treatment period, a 60-week open-label treatment period, a 120-week long-term extension, and a 28-week post-treatment follow-up. In total, the study lasts about 5 years.
  • What are the main goals of the ION373 clinical trials? The main objectives are to evaluate ION373's effectiveness in improving or stabilizing gross motor function in patients with Alexander Disease. The trials also aim to assess the drug's safety, how it moves through the body (pharmacokinetics), and its effects on the body (pharmacodynamics).

Ongoing Clinical Trials on 2′-O-(2-Methoxyethyl)-D-Ribose Antisense Oligonucleotide Targeting Glial Fibrillary Acidic Protein Messenger Ribonucleic Acid

  • Study of ION373 Given by Spinal Injection for Patients with Alexander Disease

    Not recruiting

    1
    Investigated diseases:
    Investigated drugs:
    Italy The Netherlands

Glossary

  • Alexander Disease: A rare genetic disorder that primarily affects the brain and spinal cord. It is caused by mutations in the GFAP gene and leads to the destruction of white matter in the brain.
  • Antisense Oligonucleotide: A short piece of DNA or RNA that can bind to specific messenger RNA molecules and block them from producing proteins.
  • Glial Fibrillary Acidic Protein (GFAP): A protein found in certain cells of the central nervous system called astrocytes. Mutations in the gene that produces GFAP are responsible for Alexander Disease.
  • Intrathecal Administration: A method of delivering medication directly into the fluid surrounding the brain and spinal cord through a procedure called a lumbar puncture.
  • Lumbar Puncture: A medical procedure where a needle is inserted between two vertebrae in the lower back to withdraw cerebrospinal fluid or inject medication.
  • Double-Blind Study: A type of clinical trial where neither the participants nor the researchers know who is receiving the actual treatment and who is receiving a placebo.
  • Open-Label Study: A type of clinical trial where both the researchers and participants know which treatment is being administered.
  • Pharmacokinetics: The study of how a drug moves through the body, including its absorption, distribution, metabolism, and excretion.
  • Pharmacodynamics: The study of how a drug affects the body, including its mechanism of action and relationship between drug concentration and effect.

References

  1. http://clinicaltrials.eu/trial/study-on-the-effects-of-ion373-in-patients-with-alexander-disease/